Idorsia Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0363463438
CHF
4.16
0.05 (1.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.08 M

Shareholding (Jun 2023)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 27.11% and Operating profit at 10.78% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Risky -

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 926 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

4.71%

stock-summary
Price to Book

-0.82

Revenue and Profits:
Net Sales:
72 Million
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.08%
0%
15.08%
6 Months
100.48%
0%
100.48%
1 Year
203.65%
0%
203.65%
2 Years
113.55%
0%
113.55%
3 Years
-69.21%
0%
-69.21%
4 Years
-74.54%
0%
-74.54%
5 Years
-83.43%
0%
-83.43%

Idorsia Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
27.11%
EBIT Growth (5y)
10.78%
EBIT to Interest (avg)
-28.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.95
Sales to Capital Employed (avg)
0.25
Tax Ratio
0.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.83
EV to EBIT
-11.99
EV to EBITDA
-13.42
EV to Capital Employed
-64.75
EV to Sales
9.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 22.58% vs -1.67% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -118.07% vs 175.12% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "72.20",
          "val2": "58.90",
          "chgp": "22.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.40",
          "val2": "-20.70",
          "chgp": "88.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.70",
          "val2": "7.50",
          "chgp": "16.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "-0.60",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.40",
          "val2": "63.10",
          "chgp": "-118.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-101.40%",
          "val2": "-425.20%",
          "chgp": "32.38%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -26.18% vs 56.95% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.45% vs 64.02% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "112.50",
          "val2": "152.40",
          "chgp": "-26.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-325.60",
          "val2": "-524.00",
          "chgp": "37.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "20.10",
          "val2": "20.70",
          "chgp": "-2.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-26.10",
          "val2": "-19.20",
          "chgp": "-35.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-263.80",
          "val2": "-297.90",
          "chgp": "11.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,053.00%",
          "val2": "-3,563.70%",
          "chgp": "51.07%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
72.20
58.90
22.58%
Operating Profit (PBDIT) excl Other Income
-2.40
-20.70
88.41%
Interest
8.70
7.50
16.00%
Exceptional Items
-0.30
-0.60
50.00%
Consolidate Net Profit
-11.40
63.10
-118.07%
Operating Profit Margin (Excl OI)
-101.40%
-425.20%
32.38%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 22.58% vs -1.67% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -118.07% vs 175.12% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
112.50
152.40
-26.18%
Operating Profit (PBDIT) excl Other Income
-325.60
-524.00
37.86%
Interest
20.10
20.70
-2.90%
Exceptional Items
-26.10
-19.20
-35.94%
Consolidate Net Profit
-263.80
-297.90
11.45%
Operating Profit Margin (Excl OI)
-3,053.00%
-3,563.70%
51.07%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -26.18% vs 56.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 11.45% vs 64.02% in Dec 2023

stock-summaryCompany CV
About Idorsia Ltd. stock-summary
stock-summary
Idorsia Ltd.
Pharmaceuticals & Biotechnology
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Company Coordinates stock-summary
Company Details
Hegenheimermattweg 91 , ALLSCHWIL None : 4123
stock-summary
Tel: 41 58 8441010
stock-summary
Registrar Details